G. Perini, L.C. Bergamo - Vol. 10, June 2004, Issue 2
Testo Immagini Bibliografia Summary Indice
Nuovi orientamenti per il trattamento delle
fasi acute della schizofrenia
New perspectives in the treatment of acute phases of schizophrenia
1 WHO, The World Health Report 2001: Burden of Mental Diseases.
2 Liberman J. The Early Stages of Schizophrenia: Speculation on Pathogenesis, Pathophysiology and Therapeutic Approaches. Biol Psychiatry 2001;50:825-44. Review.
3 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, et al. Prefrontal cortex and the genetics of schizophrenia. Biol Psychiatry 2001;50:884-97.
4 Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of Clozapine, Olanzapine, Risperidone and Aloperidol in patients with Chronic Schizophrenia or Schizoaffective disorder. Am J Psychiatry 2002;159:1018-28.
5 Linee guida per la farmacoterapia della schizofrenia. Consensus Conference, Roma, 14-15 aprile 2000. Giorn Ital Psicopatol 2000; 6, suppl.
6 Taylor D, McConnel D, Mc Connell H, Kerwin R. Le linee guida per la terapia psicofarmacologica, preparate dal Maudsley Hospital, Londra, Martin Dunitz Ed. Italiana (a cura di Pariante C, Dazzan P), 2002.
7 Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of the atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-9.
8 Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38.
9 Davis JM, Chen N, Glick ID. A meta-analysis of the Efficacy of Second Generation Antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
10 Practice Guideline for the treatment of patients with schizophrenia: American Psychiatric Association. Am J Psychiatry 1997;154(4 Suppl):1-63
11 Thornley B, Adams CE, Awad G. Chlorpromazine versus placebo for those with schizophrenia. In: The Cochrane Library, Issue 2,2000. Oxford.
12 Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indarn S. Olanzapine for schizophrenia. In: The Cochrane Library, Issue 2, Oxford, 2000.
13 Leucht S, Pitschel-Walz G, Abrhaam D, Kissling W. Efficacy and extrapiramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophrenia Res 1999;35:51-68.
14 Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramusuclar haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001;158:1149-51.
15 Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001;62(S):22-4.
16 Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramusuclar olanzzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002;59:441-8.
17 Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther 2003;25:1420-8.
18 Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs aloperidol and placebo on QT interval in acutely agitated patients. Psychiatry Res 2003;119:113-23.
19 Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramusular olanzapine in agitated patients. Am J Emerg Med 2003;21:192-8.
20 Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. A double-blind, randomized comparison of the efficacy and safety of Intramuscular injection of olanzapine, lorazepam or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97.
21 Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropychopharmacology 2002;26:494-504.
22 Kennedy JS, Song F, Hunter R, Clarke Q, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. In: The Cochrane Library, Issue 2, Oxford, 2000.
23 Srisurapanont M, Disayavanish C, Taimkaew K. Quetiapine for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 1999. Oxford: Update software.
24 Bellantuono C, Tentoni L. Farmaci antipsicotici e rischio di diabete: un approccio evidence-based. It J Psychopathol 2003;9:1-13.
25 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologist, North American Association for The Study of Obesity, Consensus Development Conference on antipsychotic drug and obesity and diabetes. Diabetes Care 2004;27:2.
26 Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
27 Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-70.
28 Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry 2003;160:290-6.